These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28483960)

  • 21. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius.
    Awji EG; Tassew DD; Lee JS; Lee SJ; Choi MJ; Reza MA; Rhee MH; Kim TH; Park SC
    Vet Dermatol; 2012 Aug; 23(4):376-80, e68-9. PubMed ID: 22409306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
    Alou L; Giménez MJ; Sevillano D; Aguilar L; Cafini F; Echeverría O; Pérez-Trallero E; Prieto J
    J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to fluoroquinolones by the combination of target site mutations and enhanced expression of genes for efflux pumps in Shigella flexneri and Shigella sonnei strains isolated in Korea.
    Kim JY; Kim SH; Jeon SM; Park MS; Rhie HG; Lee BK
    Clin Microbiol Infect; 2008 Aug; 14(8):760-5. PubMed ID: 18727800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative mutant prevention concentration and antibacterial activity of fluoroquinolones against Escherichia coli in diarrheic buffalo calves.
    Beri S; Sidhu PK; Kaur G; Chandra M; Rampal S
    J Chemother; 2015 Oct; 27(5):312-6. PubMed ID: 24575977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of fluoroquinolone-resistant Shigella flexneri in Hangzhou area of China.
    Pu XY; Pan JC; Wang HQ; Zhang W; Huang ZC; Gu YM
    J Antimicrob Chemother; 2009 May; 63(5):917-20. PubMed ID: 19297378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone.
    Starnino S; ; Galarza P; Carvallo ME; Benzaken AS; Ballesteros AM; Cruz OM; Hernandez AL; Carbajal JL; Borthagaray G; Payares D; Dillon JA
    Sex Transm Dis; 2012 Oct; 39(10):813-21. PubMed ID: 23001269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
    Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
    J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
    Nakase K; Sakuma Y; Nakaminami H; Noguchi N
    Anaerobe; 2016 Dec; 42():166-171. PubMed ID: 27793740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
    Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
    Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone.
    Drago L; Mattina R; Legnani D; Romano CL; Vianello E; Ricci C; De Vecchi E
    Int J Immunopathol Pharmacol; 2011; 24(4):1027-35. PubMed ID: 22230408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
    Linde HJ; Lehn N
    J Antimicrob Chemother; 2004 Feb; 53(2):252-7. PubMed ID: 14688048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
    Homma T; Hori T; Sugimori G; Yamano Y
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shigella flexneri with Ciprofloxacin Resistance and Reduced Azithromycin Susceptibility, Canada, 2015.
    Gaudreau C; Pilon PA; Cornut G; Marchand-Senecal X; Bekal S
    Emerg Infect Dis; 2016 Nov; 22(11):2016-2018. PubMed ID: 27767915
    [No Abstract]   [Full Text] [Related]  

  • 40. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.